Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Código da empresaOCSAW
Nome da EmpresaOculis Holding AG
Data de listagemMar 03, 2023
CEODr. Riad Sherif, M.D.
Número de funcionários- -
Tipo de títulosCompany Warrant
Fim do ano fiscal- -
EndereçoBahnhofstrasse 20
CidadeZUG
Bolsa de valoresNASDAQ Global Market Consolidated
PaísSwitzerland
Código postal6300
Telefone41417113960
Sitehttps://oculis.com/
Código da empresaOCSAW
Data de listagemMar 03, 2023
CEODr. Riad Sherif, M.D.
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados